Levetiracetam Crescent 100mg/ml Oral Solution 4+ Years 300ml

Levetiracetam Crescent 100mg/ml Oral Solution 4+ Years 300ml is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).

Levetiracetam Crescent 100mg/ml Oral Solution 4+ Years 300ml is used:

  • on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas in both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.
  • as an add-on to other antiepileptic medicines to treat:
    • partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age
    • myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy
    • primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Please contact Crescent Pharma should you require any more information.

Category:

Description

Description

Therapeutic Indications for Levetiracetam Crescent 100mg/ml Oral Solution 4+ Years 300ml

Levetiracetam Crescent 100mg/ml Oral Solution 4+ Years 300ml is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. 

Levetiracetam Crescent 100mg/ml Oral Solution 4+ Years 300ml is indicated as adjunctive therapy 

• in the treatment of partial onset seizures with or without secondary generalisation in adults adolescents, and children from 1 month of age with epilepsy. 

• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. 

• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Please contact Crescent Pharma should you require any more information.